Compile Data Set for Download or QSAR
Report error Found 19 Enz. Inhib. hit(s) with all data for entry = 2664
TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375312(US9908872, Compound (I-9))
Affinity DataIC50: 2.43nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375310(US9908872, Compound (I-8))
Affinity DataIC50: 5.33nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 7.40nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375281(US9908872, Compound (I-4) | US10597387, Compound (...)
Affinity DataIC50: 22.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 22.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375312(US9908872, Compound (I-9))
Affinity DataIC50: 25.3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 29.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375308(US9908872, Compound (I-7) | US10597387, Compound (...)
Affinity DataIC50: 56.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375280(US9908872, Compound (I-3) | US10597387, Compound (...)
Affinity DataIC50: 62.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375310(US9908872, Compound (I-8))
Affinity DataIC50: 69.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375299(US9908872, Compound (I-5) | US10597387, Compound (...)
Affinity DataIC50: 117nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375280(US9908872, Compound (I-3) | US10597387, Compound (...)
Affinity DataIC50: 196nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375281(US9908872, Compound (I-4) | US10597387, Compound (...)
Affinity DataIC50: 459nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 1.15E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 3.33E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375308(US9908872, Compound (I-7) | US10597387, Compound (...)
Affinity DataIC50: 3.42E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375299(US9908872, Compound (I-5) | US10597387, Compound (...)
Affinity DataIC50: 3.91E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 8.21E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375299(US9908872, Compound (I-5) | US10597387, Compound (...)
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent